Literature DB >> 15703342

Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths.

Julie Magno Zito1, Daniel J Safer, Ilene H Zuckerman, James F Gardner, Karen Soeken.   

Abstract

OBJECTIVE: This study sought to determine the degree to which Medicaid eligibility categories modify disparities between black and white youths in the prevalence of psychotropic medication.
METHODS: Computerized claims for 189,486 youths aged two to 19 years who were continuously enrolled in a mid-Atlantic state Medicaid program for the year 2000 were analyzed to determine population-based annual prevalence of psychotropic medication by race or ethnicity and by whether the youths were eligible for Medicaid for reasons of family income, disability, or foster care placement. Logistic regression was used to assess the interaction of eligibility category and race.
RESULTS: The mean annual prevalence of psychotropic medication for the population was 9.9 percent. The prevalence was 2.17 times higher for white youths than for black youths (16.5 percent compared with 7.6 percent). However, within eligibility categories, the white-to-black disparity was 3.8 among youths who were eligible for Medicaid because their family income was below the federal poverty level and 3.2 for youths enrolled in the State Children's Health Insurance Program.
CONCLUSIONS: Medicaid eligibility categories had a profound impact on the racial disparity associated with the prevalence of psychotropic medications for youths. Eligibility category should be taken into account when ascertaining the role of access, undertreatment, and culture in disparities in mental health treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15703342     DOI: 10.1176/appi.ps.56.2.157

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  21 in total

Review 1.  Parental preferences and goals regarding ADHD treatment.

Authors:  Alexander G Fiks; Stephanie Mayne; Elena Debartolo; Thomas J Power; James P Guevara
Journal:  Pediatrics       Date:  2013-09-02       Impact factor: 7.124

2.  Child sociodemographic characteristics and common psychiatric diagnoses in medicaid encounter data: are they valid?

Authors:  Penelope K Knapp; Michael S Hurlburt; Eric C Kostello; Heather Ladd; Lingqi Tang; Bonnie T Zima
Journal:  J Behav Health Serv Res       Date:  2006-10       Impact factor: 1.505

3.  Utilizing new prescription drugs: disparities among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites.

Authors:  Junling Wang; Ilene H Zuckerman; Nancy A Miller; Fadia T Shaya; Jason M Noel; C Daniel Mullins
Journal:  Health Serv Res       Date:  2007-08       Impact factor: 3.402

4.  Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008.

Authors:  Rebecca E Rosenberg; David S Mandell; Janet E Farmer; J Kiely Law; Alison R Marvin; Paul A Law
Journal:  J Autism Dev Disord       Date:  2010-03

5.  Antipsychotic treatment among youth in foster care.

Authors:  Susan Dosreis; Yesel Yoon; David M Rubin; Mark A Riddle; Elizabeth Noll; Aileen Rothbard
Journal:  Pediatrics       Date:  2011-11-21       Impact factor: 7.124

6.  Attitudes about stimulant medication for attention-deficit/hyperactivity disorder among African American families in an inner city community.

Authors:  Susan dosReis; Arlene Butz; Paul H Lipkin; Julia S Anixt; Courtney L Weiner; Robin Chernoff
Journal:  J Behav Health Serv Res       Date:  2006-10       Impact factor: 1.505

7.  Predictors of adequate depression treatment among Medicaid-enrolled youth.

Authors:  Bradley D Stein; Mark J Sorbero; Erin Dalton; Amanda M Ayers; Carrie Farmer; Jane N Kogan; Upasna Goswami
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-10-30       Impact factor: 4.328

8.  Development of an instrument to measure parents' preferences and goals for the treatment of attention deficit-hyperactivity disorder.

Authors:  Alexander G Fiks; Stephanie Mayne; Cayce C Hughes; Elena Debartolo; Carina Behrens; James P Guevara; Thomas Power
Journal:  Acad Pediatr       Date:  2012-06-28       Impact factor: 3.107

9.  Antidepressant and antipsychotic use and adherence among Medicaid youths: differences by race.

Authors:  Betsy Sleath; Marisa E Domino; Elizabeth Wiley-Exley; Bradley Martin; Shirley Richards; Tim Carey
Journal:  Community Ment Health J       Date:  2009-12-20

10.  Predictors of adequate depression treatment among Medicaid-enrolled adults.

Authors:  Carrie Farmer Teh; Mark J Sorbero; Mark J Mihalyo; Jane N Kogan; James Schuster; Charles F Reynolds; Bradley D Stein
Journal:  Health Serv Res       Date:  2009-10-29       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.